Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Its lead product candidate, KZR-616, a selective immunoproteasome inhibitor that is in Phase 1b/2 clinical trials in lupus and lupus nephritis The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Receive KZR News and Ratings via Email

Sign-up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter.

Profitability

Miscellaneous

Kezar Life Sciences (NASDAQ:KZR) Frequently Asked Questions

What is Kezar Life Sciences' stock symbol?

Kezar Life Sciences trades on the NASDAQ under the ticker symbol "KZR."

How were Kezar Life Sciences' earnings last quarter?

Kezar Life Sciences Inc (NASDAQ:KZR) posted its quarterly earnings data on Thursday, November, 8th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.18. View Kezar Life Sciences' Earnings History.

When is Kezar Life Sciences' next earnings date?

What price target have analysts set for KZR?

4 equities research analysts have issued 12-month price targets for Kezar Life Sciences' stock. Their forecasts range from $23.00 to $30.00. On average, they anticipate Kezar Life Sciences' share price to reach $26.50 in the next twelve months. This suggests a possible upside of 28.8% from the stock's current price. View Analyst Price Targets for Kezar Life Sciences.

What is the consensus analysts' recommendation for Kezar Life Sciences?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kezar Life Sciences.

Has Kezar Life Sciences been receiving favorable news coverage?

Media coverage about KZR stock has been trending positive this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Kezar Life Sciences earned a media sentiment score of 2.7 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days.

When did Kezar Life Sciences IPO?

(KZR) raised $70 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair acted as the underwriters for the IPO.

When did Kezar Life Sciences' lock-up period expire?

Kezar Life Sciences' lock-up period expired on Tuesday, December 18th. Kezar Life Sciences had issued 5,000,000 shares in its public offering on June 21st. The total size of the offering was $75,000,000 based on an initial share price of $15.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the end of the lock-up period.

How do I buy shares of Kezar Life Sciences?

Shares of KZR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kezar Life Sciences' stock price today?

One share of KZR stock can currently be purchased for approximately $20.57.

How big of a company is Kezar Life Sciences?

Kezar Life Sciences has a market capitalization of $393.06 million. Kezar Life Sciences employs 20 workers across the globe.

MarketBeat Community Rating for Kezar Life Sciences (NASDAQ KZR)

MarketBeat's community ratings are surveys of what our community members think about Kezar Life Sciences and other stocks. Vote "Outperform" if you believe KZR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KZR will underperform the S&P 500 over the long term. You may vote once every thirty days.